Accueil・Liste d'Actions・CytoSorbents Corp

CytoSorbents Corp

Fermé

SecteurSoins de santé

0.36

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

0.35

Max

0.36

Chiffres clés
By Trading Economics
Revenu	-4.4M -9.5M
Ventes	769K 9.6M
BPA	-0.07
Marge bénéficiaire	-99.107
Employés	129
EBITDA	547K -3.3M

Recommandations
By TipRanks
Recommandations	Neutre
Prévisions sur 12 Mois	+108.33% upside

Dividendes
By Acuity
Prochains Résultats	12 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-383K 23M
Ouverture précédente	0.36
Clôture précédente	0.36

Sentiment de l'Actualité

By Acuity

50%

135 / 340 Classement par Healthcare

CytoSorbents Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

11 août 2026, 22:01 UTC

Cytosorbents Corp shares are higher in after-market trading, following notable activity after the market closed, despite no specific company news identified.

10 août 2026, 19:21 UTC

News

Cytosorbents Corp shares are higher, driven by gains in the Health Care Equipment sector. The company reported Q2 revenue of $9.63 million, exceeding forecasts.

7 août 2026, 20:51 UTC

Cytosorbents Corp shares declined in after-hours trading, continuing lower since Friday's close, with no specific news identified to explain the movement.

6 août 2026, 19:16 UTC

Cytosorbents Corp shares are higher during Thursday's session, continuing a strong upward trend since Wednesday's close, with no specific news identified for the increase.

5 août 2026, 22:06 UTC

Cytosorbents Corp shares are higher in after-market trading, reaching a high of 2.63% following an initial dip. The stock remains above its 20-day moving average.

4 août 2026, 21:01 UTC

Cytosorbents Corp shares are higher in after-market trading amid positive market sentiment linked to U.S.-Iran negotiations and declining crude oil prices.

3 août 2026, 19:56 UTC

Cytosorbents Corp shares are higher during Monday's session, tracking a broader market uptick despite being below the 20-day moving average.

31 juil. 2026, 20:06 UTC

Cytosorbents Corp. shares are trading roughly flat amid no specific news. The broader market also closed near unchanged since Thursday.

29 juil. 2026, 20:08 UTC

Cytosorbents Corp shares are lower today, following an early peak and trading below the 20-day moving average. No specific news was identified for the decline.

28 juil. 2026, 18:46 UTC

Cytosorbents Corp is trading higher during Tuesday's session, recovering from an earlier dip. No specific news was identified to explain the movement.

27 juil. 2026, 18:41 UTC

Cytosorbents Corp shares are lower today amid notable volatility, with no specific news identified to explain the decline during Monday's session.

24 juil. 2026, 19:06 UTC

Cytosorbents Corp shares are lower, marking three consecutive daily declines amid a broader market pullback influenced by falling crude oil prices.

22 juil. 2026, 20:13 UTC

Cytosorbents Corp shares are lower in after-market hours amid rising crude oil prices and escalating U.S.-Iran tensions. The stock remains below its 20-day moving average.

21 juil. 2026, 18:31 UTC

Cytosorbents Corp shares are higher today, reflecting broader market optimism despite earlier fluctuations. Strong buying in technology stocks supports this upward movement.

20 juil. 2026, 19:16 UTC

News

Cytosorbents plans to report second-quarter 2026 results on August 6. The company is also pursuing FDA and Health Canada approval for its DrugSorb®-ATR device.

Comparaison

Variation de prix

CytoSorbents Corp prévision

Objectif de Prix

By TipRanks

108.33% hausse

Prévisions sur 12 Mois

Moyen 0.75 USD 108.33%

Haut 0.75 USD

Bas 0.75 USD

Basé sur 1 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

1 ratings

Achat

Maintien

Vente

Basé sur 1 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

135 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos CytoSorbents Corp

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.